Susquehanna International Group’s Regulus Therapeutics RGLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-84,200
| Closed | -$147K | – | 13559 |
|
|
2025
Q1 | $147K | Buy |
84,200
+70,500
| +515% | +$93K | ﹤0.01% | 11246 |
|
|
2024
Q4 | $21.6K | Sell |
13,700
-22,700
| -62% | -$34.9K | ﹤0.01% | 11902 |
|
|
2024
Q3 | $57.1K | Sell |
36,400
-77,400
| -68% | -$128K | ﹤0.01% | 11325 |
|
|
2024
Q2 | $204K | Sell |
113,800
-88,500
| -44% | -$205K | ﹤0.01% | 10322 |
|
|
2024
Q1 | $583K | Buy |
202,300
+165,600
| +451% | +$270K | ﹤0.01% | 8136 |
|
|
2023
Q4 | $47K | Buy |
36,700
+1,500
| +4% | +$2K | ﹤0.01% | 11737 |
|
|
2023
Q3 | $48.6K | Sell |
35,200
-8,800
| -20% | -$12.8K | ﹤0.01% | 11321 |
|
|
2023
Q2 | $64.7K | Buy |
44,000
+3,300
| +8% | +$4.4K | ﹤0.01% | 11221 |
|
|
2023
Q1 | $34.6K | Sell |
40,700
-1,700
| -4% | -$2.25K | ﹤0.01% | 11855 |
|
|
2022
Q4 | $58.1K | Buy |
42,400
+3,900
| +10% | +$6.13K | ﹤0.01% | 11315 |
|
|
2022
Q3 | $65K | Buy |
38,500
+15,300
| +66% | +$27.5K | ﹤0.01% | 12037 |
|
|
2022
Q2 | $48K | Buy |
23,200
+20,500
| +759% | +$49.8K | ﹤0.01% | 11997 |
|
|
2022
Q1 | $8K | Sell |
2,700
-5,430
| -67% | -$14.1K | ﹤0.01% | 12775 |
|
|
2021
Q4 | $26K | Sell |
8,130
-15,660
| -66% | -$69.6K | ﹤0.01% | 12774 |
|
|
2021
Q3 | $164K | Sell |
23,790
-3,440
| -13% | -$25.2K | ﹤0.01% | 11715 |
|
|
2021
Q2 | $221K | Buy |
27,230
+8,450
| +45% | +$94.3K | ﹤0.01% | 11389 |
|
|
2021
Q1 | $293K | Buy |
18,780
+13,440
| +252% | +$199K | ﹤0.01% | 10651 |
|
|
2020
Q4 | $72K | Buy |
+5,340
| New | +$39.2K | ﹤0.01% | 10634 |
|
|
2016
Q3 | – | Sell |
-2,075
| Closed | -$720K | – | 8922 |
|
|
2016
Q2 | $720K | Buy |
2,075
+1,592
| +330% | +$1.14M | ﹤0.01% | 5482 |
|
|
2016
Q1 | $402K | Buy |
483
+87
| +22% | +$69.2K | ﹤0.01% | 6774 |
|
|
2015
Q4 | $414K | Buy |
396
+8
| +2% | +$8.02K | ﹤0.01% | 7124 |
|
|
2015
Q3 | $304K | Sell |
388
-62
| -14% | -$63.6K | ﹤0.01% | 8022 |
|
|
2015
Q2 | $592K | Sell |
450
-759
| -63% | -$1.22M | ﹤0.01% | 7285 |
|
|
2015
Q1 | $2.46M | Sell |
1,209
-112
| -8% | -$243K | ﹤0.01% | 3906 |
|
|
2014
Q4 | $2.54M | Buy |
+1,321
| New | +$2.35M | ﹤0.01% | 4006 |
|
Other funds holding RGLS
Susquehanna International Group's RGLS Position: Q2 2025 in Review
Susquehanna International Group sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 150,813 shares — an estimated $264K sold.
Susquehanna International Group first reported a position in RGLS in Q4 2014 and held it in 22 quarters. The position peaked at $2.5M in Q3 2015. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.
- Susquehanna International Group reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
- Susquehanna International Group sold 150,813 Regulus Therapeutics shares in Q2 2025, an estimated $264K.
- Susquehanna International Group first reported a position in Regulus Therapeutics in Q4 2014 and held it in 22 quarters.
- Susquehanna International Group's Regulus Therapeutics position peaked at $2.5M in Q3 2015.
- 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.
Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.